Lirilumab

Lirilumab (INN) is a human monoclonal antibody designed for the treatment of cancer.^[1][2] It binds to KIR2DL1/2/3.^[3]

Lirilumab

Monoclonal antibody
Type	Whole antibody
Source	Human
Target	KIR2DL1/2/3
Clinical data
ATC code	none
Identifiers
CAS Number	1000676-41-4
ChemSpider	none
UNII	S9XDI9W918
KEGG	D10444
Chemical and physical data
Formula	C6452H9918N1698O2030S46
Molar mass	145228.93 g·mol−1

This drug was developed by Innate Pharma and is licensed to Bristol-Myers Squibb.

Clinical trials

A phase 2 clinical trial for acute myeloid leukemia (AML)^[4] was terminated early ("failed") in 2017.^[5]

It was registered for a trial for squamous cell carcinoma of the head and neck (SCCHN),^[6] but it may be abandoned.^[7]

As of November 2017^[update] nine clinical trials of lirilumab are registered as active.^[8]